Shindo H, Tawata M, Inoue M, Yokomori N, Hosaka Y, Ohtaka M, Onaya T
Third Department of Internal Medicine, University of Yamanashi Medical School, Japan.
Diabetes Res Clin Pract. 1994 Jul;24(3):173-80. doi: 10.1016/0168-8227(94)90113-9.
We studied the effect of prostaglandin E1.alpha CD (PGE1) on diabetic peripheral neuropathy by evaluating subjective symptoms and vibration sensation using a new vibrometer (SMV-5). Patients with diabetic neuropathy (n = 38) were divided into three groups; group A received no drugs (control), group B was treated with 1500 micrograms/day of oral methyl vitamin B12 (VB12) for four weeks, and group C received 1.2 micrograms/kg/day PGE1 intravenously for four weeks. There was a close relationship between symptom scores and vibratory threshold (VT). The effect of PGE1 on subjective symptoms and VT were compared with those in groups A and B. Patients who received PGE1 showed a significant improvement rate in pain and hypesthesia compared to patients in groups A and B, and in numbness compared to group A. During the study period, there was no significant change in VT in groups A and B, whereas VT was significantly improved at styloid process (P < 0.05) and at medial malleolus (P < 0.001) in group C. Our results confirmed that PGE1 significantly improved both subjective symptoms and VT, indicating that PGE1 therapy may be useful in diabetic neuropathy.
我们通过使用一种新型振动计（SMV - 5）评估主观症状和振动觉，研究了前列腺素E1α环糊精（PGE1）对糖尿病周围神经病变的影响。糖尿病神经病变患者（n = 38）被分为三组；A组未接受任何药物治疗（对照组），B组接受为期四周的每日1500微克口服甲钴胺（VB12）治疗，C组接受为期四周的每日1.2微克/千克静脉注射PGE1治疗。症状评分与振动阈值（VT）之间存在密切关系。将PGE1对主观症状和VT的影响与A组和B组进行比较。与A组和B组患者相比，接受PGE1治疗的患者在疼痛和感觉减退方面显示出显著的改善率，与A组相比在麻木方面也有显著改善。在研究期间，A组和B组的VT无显著变化，而C组在茎突处（P < 0.05）和内踝处（P < 0.001）的VT显著改善。我们的结果证实，PGE1能显著改善主观症状和VT，表明PGE1治疗可能对糖尿病神经病变有效。
